Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus RIFAXIMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus RIFAXIMIN.
NEO-FRADIN vs RIFAXIMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Rifaximin is a non-aminoglycoside, semi-synthetic antibiotic derived from rifamycin that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby blocking transcription.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
550 mg orally three times daily for 14 days for travelers' diarrhea; 200 mg orally three times daily for 3 days for irritable bowel syndrome with diarrhea; 400 mg orally three times daily for 7 days for hepatic encephalopathy.
None Documented
None Documented
Clinical Note
moderateRifaximin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Tranilast
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
The terminal elimination half-life is approximately 1.8 to 2.5 hours in patients with normal hepatic function. Due to negligible systemic absorption, the half-life has limited clinical relevance; drug action is largely confined to the gastrointestinal tract.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Rifaximin is primarily eliminated in feces as unchanged drug (>96% of an oral dose). Renal excretion is negligible (<0.4%). Biliary excretion is minimal due to poor systemic absorption.
Category C
Category A/B
Antibiotic
Antibiotic
"The serum concentration of Tranilast can be decreased when it is combined with Rifaximin."